RSV Vaccine Market Poised for Growth as Pfizer, Sanofi Gain Approvals

The respiratory syncytial virus (RSV) vaccine market could be worth $10 billion by 2030. Pfizer and Sanofi recently got approvals for RSV vaccines.
Pfizer's vaccine is approved for infants and older adults. Sanofi's is for infants. The market for older adults may be larger.
Other companies like Moderna are also developing RSV vaccines. The $10 billion market will be split between multiple players.
Pfizer has launched several new drugs recently, showing innovative capabilities. Its stock price has dropped in 2022 but should rebound.
Sanofi has growth drivers like eczema drug Dupixent. It also acquired a company making a diabetes prevention drug. Sanofi is a solid long-term biotech investment.

The respiratory syncytial virus (RSV) vaccine market could be worth $10 billion by 2030. Pfizer and Sanofi recently got approvals for RSV vaccines.
Pfizer's vaccine is approved for infants and older adults. Sanofi's is for infants. The market for older adults may be larger.
Other companies like Moderna are also developing RSV vaccines. The $10 billion market will be split between multiple players.
Pfizer has launched several new drugs recently, showing innovative capabilities. Its stock price has dropped in 2022 but should rebound.
Sanofi has growth drivers like eczema drug Dupixent. It also acquired a company making a diabetes prevention drug. Sanofi is a solid long-term biotech investment.